News & Events

New drug targets early instigator of Alzheimer’s disease

August 14, 2019

Over a hundred years after they were first identified, two ominous signposts of Alzheimer’s disease (AD) remain central topics of research—both formed by sticky accumulations of protein in the brain. Amyloid beta solidifies into senile plaques, which congregate in the extracellular spaces of nerve tissue, while tau protein creates tangled forms crowding the bodies of neurons. Plaques and tangles, considered classic hallmarks of AD, have been the objects of fierce debate, sustained...

Epigenetic study reveals potential for earlier diagnosis in Parkinson’s disease

April 16, 2019

Parkinson’s disease, a neurodegenerative disorder, largely affects movement and causes irreversible neuronal damage. It may start with a tremor or it may be manifested in a speech problem; however, by the time symptoms are evident, it is too late to halt the course of the disease.  PD originates from the loss of neurons releasing dopamine. Because these neurons control coordination in movement, their loss results in a multitude of movement-related deficiencies. Although there is...

Study Looks for DNA Changes to Measure Parkinson’s Disease

February 4, 2019

Researchers at University of California San Diego School of Medicine and Arizona State University (ASU) have received funding from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to launch a multiyear, $1.7 million effort to identify blood-based biomarkers of Parkinson’s disease (PD), which could improve care and accelerate new treatments for the neurodegenerative disorder, which affects nearly 1 million Americans, with 60,000 new cases diagnosed annually. “The exact...

ASU-UA-TGEN Startup Iluminos Licenses Treatment for Alzheimer’s Disease

April 25, 2018

Iluminos Therapeutics has licensed new compounds designed to treat neurodegenerative diseases, particularly Alzheimer’s. Travis Dunckley, PhD, Assistant Research Professor at the ASU-Banner Neurodegenerative Disease Research Center helped develop the new therapies with lead inventor, Christopher Hulme, PhD, Professor of Medicinal Chemistry in the UA Department of Pharmacy and Toxicology (formerly at Eli Lilly and Amgen)  and Arthur Shaw, post-doctoral research fellow at the time. The...

New study surveys genetic changes linked with Parkinson’s disease

May 24, 2016

After Alzheimer’s, Parkinson’s disease (PD) is the leading neurodegenerative disorder, affecting close to a million Americans, with 50,000 new cases diagnosed every year. A progressive disorder of the nervous system affecting movement, PD typically strikes adults in mid-life.  In many cases, the spread of the disease to other brain areas leads to Parkinson's disease dementia, characterized by deterioration of memory, reason, attention and planning. In new research, Travis Dunckley,...

Arizona State University and Banner Health launch major effort to fight neurodegenerative diseases

June 10, 2015

Tempe, Arizona – Arizona State University and Banner Health today announced a new research alliance to advance the scientific study, treatment and prevention of Alzheimer’s, Parkinson’s and other neurodegenerative diseases. The partnership between Arizona State University (ASU), one of the nation’s largest public research universities, and Phoenix-based Banner Health, one of the nation’s largest nonprofit health systems, includes the launch of a new Arizona State...